Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 May 6.
Published in final edited form as: ChemMedChem. 2016 Mar 18;11(9):963–971. doi: 10.1002/cmdc.201600065

Characterization of the Binding of Hydroxyindole, Indoleacetic acid and Morpholinoaniline to the Salmonella Type III Secretion System Proteins SipD and SipB

Andrew C McShan a, Asokan Anbanandam b, Sikta Patnaik a, Roberto N De Guzman a,*
PMCID: PMC5010876  NIHMSID: NIHMS800412  PMID: 26990667

Abstract

Many Gram-negative bacteria require the type III secretion system (T3SS) to cause infectious diseases in humans. A looming public health problem is that all bacterial pathogens that require the T3SS to cause infectious diseases in humans have developed multi-drug resistance to current antibiotics. The T3SS is an attractive target for the development of new antibiotics because of its critical role in virulence. An initial step in developing anti-T3SS based therapeutics is the identification of small molecules that can bind to T3SS proteins. Currently, the only small molecules that are known to bind to the Salmonella T3SS proteins SipD and SipB are bile salts to SipD; and sphingolipids and cholesterol to SipB. Here, we show results from a surface plasmon resonance screen of 288 compounds, which identified the binding of 4-morpholinoaniline to SipD, 3-indoleacetic acid to SipB, and 5-hydroxyindole to both SipD and SipB. We also identified by NMR the SipD surfaces involved in binding. These 3 compounds represent new molecules that can bind to T3SS tip and translocon proteins that can be potentially used for future drug design.

Keywords: type III secretion system, tip, translocon, SipD, SipB, NMR, STD NMR, small molecules, surface plasmon resonance

Graphical Abstract

graphic file with name nihms800412f12.jpg

Introduction

Salmonella, a causative agent of food borne illness and typhoid fever that is responsible for millions of infections each year worldwide,[1] and other Gram-negative bacteria belonging to the Pseudomonas, Shigella, Chlamydia, and Yersinia genera assemble the type III secretion system (T3SS) to initiate infectious diseases in humans.[2] The rise of antibiotic resistance among these pathogens coupled with the dearth of new antibiotics necessitates the development of new anti-bacterials.[3] The T3SS is an attractive target for developing new anti-bacterials because of its essential role in virulence, its exposure on the bacterial surface, and its presence only among pathogens.[3]

The function of the T3SS is to inject effector proteins into the host cytoplasm to manipulate host signaling pathways for the benefit and survival of bacteria.[2] The structural component of the T3SS is a mega-Dalton assemblage of over 20 proteins that form the needle apparatus, which consists of a base, an extracellular needle, a tip complex and a translocon.[4] In Salmonella, the tip protein is SipD and the translocon proteins are the membrane proteins SipB and SipC. The tip protein SipD is exposed to the extracellular environment prior to contact with host cells.[5] Upon contact with the host cell, the translocon assembles on the tip complex to form a pore on the host cell membrane to allow the passage of effectors into the host cell cytoplasm.[5] The crystal structure of SipD[6] and other tip proteins[7] are known. SipD contains an N-terminal α-helical hairpin, an elongated central coiled-coil and a domain of mixed α-helices and β-strands.[6] The crystal structures of the N-terminal ectodomains of the Shigella IpaB74–224 and Salmonella SipB82–226 translocon proteins show coiled-coils of three anti-parallel α-helices,[8] and the IpaB and SipB ectodomains interact directly with their tip proteins.[9]

Currently, the only known small molecules that bind to the tip protein and translocon proteins are bile salts (to SipD and its Shigella homolog, IpaD)[10] and sphingolipids and cholesterol (to SipB).[11] To identify other molecular fragments that could bind to SipD and SipB that could potentially be used as potential scaffolds for development of novel T3SS inhibitors, we screened a library of 288 compounds from a Zenobia library. We identified that 5-hydroxyindole (structure 1, Figure 1) binds to both SipD and SipB82–240, 3–indoleacetic acid (2) binds to SipB82–240, and 4-morpholinoaniline (10) binds to SipD. Our results revealed new small molecule scaffolds based on indole and morpholinoaniline that can bind to SipD and SipB.

Figure 1.

Figure 1

Structure of small molecule scaffolds. SPR identified the binding of 5-hydroxyindole (1) to SipD and SipB82–240, 3–indoleacetic acid (2) to SipB82–240, and 4-morpholinoaniline (10) to SipB82–240. The non-binding or relatively weaker binding of other similar scaffolds revealed the important functional groups needed for binding to SipD or SipB82–240.

Results

SPR screening

The expression and purification of SipD and SipB82–240 yielded milligram amounts of proteins and their solubility allowed for SPR screening followed by NMR characterization. SPR is a label free method of screening for small molecule fragments that bind proteins.[12] The SPR screen of 288 compounds from a structurally diverse library of fragment-like compounds (Zenobia Library 2) identified the binding of 5-hydroxyindole (1, Fig 1) to both SipD and SipB82–240; 3-indoleacetic acid (2) to SipB82–240; and 4-morpholinoaniline (10) SipD (Figure 2). Results of the SPR screen also identified the important functional groups within the scaffolds in binding to SipD and SipB82–240. Regarding the binding of the indole scaffold to SipD and SipB82–240, other functional groups such as hydroxyl and acetyl groups were needed for binding, as the indole ring (3) alone was incapable of binding. Replacing the 5-hydroxy group with a 5-cyano group (4) abrogated the interaction suggesting that the 5’ hydroxyl group in (1) might be needed for hydrogen bonding with SipD or SipB82–240. The acetate methylene group (in 2) was needed for binding SipB82–240 as its removal (in 5 and 6) resulted in loss of binding. Likewise, the carboxylic acid group (in 2) was important for binding as its removal (in 7, 8, 9) resulted in loss of binding. Regarding the binding of the morpholinoaniline (10) scaffold to SipD, hydroxylation or removal of the amino group (in 11) or introducing a methylene group between the two rings (in 12) resulted in loss of binding.

Figure 2.

Figure 2

SPR screening of SipD and SipB82–240. SPR sensorgrams showing the binding of A) 5-hydroxyindole to SipD, B) 4-morpholinoaniline to SipB82–240, C) 5-hydroxyindole to SipD, and D) 3-indoleacetic acid to SipB82–240.

NMR titrations of SipD with 5-hydroxyindole

NMR was used to characterize the interaction of SipD with 5-hydroxyindole. SipD uniformly labeled with both 15N and ILV was titrated with 5-hydroxyindole at increasing molar ratios of 1:0, 1:25, 1:50 and 1:100 and the titration was monitored by acquiring 2D 1H-15N TROSY and 2D 1H-13C HSQC datasets. Titration of SipD with 5-hydroxyindole resulted in chemical shift perturbations of specific SipD amide peaks in a concentration dependent manner (Figure 3). SipD residues that were affected by binding (e.g. E133, M174, G175, L179, N211 and W234ε) showed progressive changes in their peak positions indicating interaction in fast exchange NMR time scale. In addition to the 15N resonances of SipD, the ILV 13C methyl groups of SipD were also used as probes of the interaction (Figure 4). Like the results of 15N titration, titration with 5-hydroxyindole resulted in chemical shift perturbations of specific SipD ILV peaks in a concentration dependent manner (Figure 4). Based on the chemical shift deviations of 15N data (for E133, M174, G175 and L179, Figure 3B) and ILV data (for L48, L178 and V187, Figure 4B), the dissociation constant for the binding of 5-hydroxyindole to SipD was estimated to be 32 ± 8 mM.

Figure 3.

Figure 3

15N NMR titration of SipD with 5-hydroxyindole. A) Overlay of five 2D 1H-15N TROSY spectra of 15N/ILV-labeled SipD titrated with increasing molar ratios of 5-hydroxyindole, with expanded sections for selected SipD residues affected by the interaction with 5-hydroxyindole. B) Plot of chemical shift deviation (CSD) vs concentration of 5-hydroxyindole for selected residues.

Figure 4.

Figure 4

ILV titration of SipD with 5-hydroxyindole. A) Overlay of five 2D 1H-13C HSQC spectra of SipD titrated with increasing mole ratio of 5-hydroxyindole. B) Plots of chemical shift deviation (CSD) vs concentration of 5-hydroxyindole for selected 13C methyl peaks.

The chemical shift deviation for each non-overlapped amide (Figure 5A) and ILV (Figure 5B) peak of SipD identified the residues that were strongly affected by binding of 5-hydroxyindole. Results of the 15N titration showed that the SipD residues affected by 5-hydroxyindole ranged from hydrophobic (L97, A115, I134, L171, G175, L179, V187) to polar charged (R106, R126, E133, K188, K302) residues (Figure 5A). The ILV titrations confirmed the results of the 15N titration as many residues such as I134, L171 and V187 identified in the 15N titration also showed significant chemical shift deviations in the ILV titration with 5-hydroxyindole. Additionally, the ILV titrations identified other residues (I45, V253, V323, Figure 5B) that were not previously identified in the 15N titration that showed significant chemical shift deviation upon binding to 5-hydroxyindole. The methyl side chains of I45, V253, and V323 were likely involved in hydrophobic contacts with 5-hydroxyindole.

Figure 5.

Figure 5

Plots of chemical shift deviations of SipD with 5-hydroxyindole. Chemical shift deviations from A) 15N and B) ILV titrations of SipD with 5-hydroxyindole (σ, average CSD).

The residues that showed significant chemical shift deviations clustered on two surfaces on SipD (Figure 6). One surface maps at the mixed α/β domain (involving residues G175, L178, and V187). The second larger surface maps near the bottom of the coiled-coil and is formed by S110, S114, and R126 in the 23-residue loop spanning residues 110–132 that connects the α-helical hairpin to the coiled-coil. I45 in the α-helical hairpin and I134 in the coiled-coil show strong chemical shift deviations. Our results suggest that 5-hydroxyindole binds at the bottom of the coiled coil and the loop 110–132 because most of the residues affected by interaction are in this region. The other site that showed chemical shift deviations perhaps indicate transient, weaker interactions with 5-hydroxyindole.

Figure 6.

Figure 6

SipD surfaces affected by binding of 5-hydroxyindole. Cα of SipD colored according to 15N and ILV chemical shift deviations as follows 1σ (yellow), 2σ (orange), 3σ (red); where σ is the standard deviation from average CSD in Figure 5.

STD NMR of 5-hydroxyindole with SipD

Results of 1H STD NMR experiments identified which parts of 5-hydroxyindole were needed for binding to SipD. As expected, the off-resonance reference spectrum shows NMR peaks from both SipD and 5-hydroxyindole (Figure 7A). The resulting 1H STD NMR spectrum shows all the NMR peaks corresponding to 5-hydroxyindole remained above noise level (Figure 7B). This indicated that, with the exception of the –OH group for which there was no NMR peak in the STD NMR, all the protons in 5-hydroxyindole were affected by the interaction with SipD. This suggested that the entire molecule of 5-hydroxyindole was embedded in SipD upon binding. As control experiment, irradiation of 5-hydroxyindole using the same conditions in the absence of SipD did not result in STD peaks, indicating that the observed STD peaks were not due to indirect saturation of 5-hydroxyindole (Figure 7C).

Figure 7.

Figure 7

STD NMR of 5-hydroxyindole with SipD. A) Off-resonance, B) on-resonance STD NMR spectra of 5-hydroxyindole with SipD, and C) STD NMR spectrum of 5-hydroxyindole in the absence of SipD.

SipD binds to 4-morpholinoaniline

In addition to 5-hydroxyindole, SPR identified the binding of another scaffold, 4-morpholinoaniline, to SipD (Figure 2B). Titration of 15N/ILV-labeled SipD with 4-morpholinoaniline at molar ratios of 1:0, 1:25, 1:50 and 1:100 resulted in distinct chemical shift deviations of specific SipD peaks in a concentration dependent manner as monitored by 15N TROSY and 13C HSQC (Figure 8 and Figure S1). Representative panels from the 15N titration (S110, A111, F117, E133, V187 and K188, Figure 8A) and ILV titrations (L138, L171, L178, V187 and L194, Figure 8B) showed peaks in fast exchange NMR time scale. Plots of the weighted chemical shift deviations (Figure 8C,D) identified the SipD residues that were strongly affected by 4-morpholinoaniline. These residues ranged from hydrophobic (G94, A111, F117, V138, L150, V156, L179 and V213) to polar charged (D131, E133, K188, K279) residues (Figure 8C). The dissociation constant, however, could not be estimated as plots of chemical shift deviations vs. concentrations of 4-morpholinoaniline did not reach saturation. STD NMR signals were not observed because SipD could not be selectively saturated as there are proton resonances of 4-morpholinoaniline near the STD NMR irradiation frequency. Nevertheless, mapping the SipD residues affected by 4-morpholinoaniline showed two distinct surfaces: the top of the mixed α/β domain and near the bottom of the coiled-coil (Figure 9), similar to the surface maps of SipD interaction with 5-hydroxyindole (Figure 6). Results with 5-hydroxyindole and 4-morpholinoaniline suggest that these surfaces in SipD could be hotspots for binding small molecule fragments.

Figure 8.

Figure 8

NMR titrations of SipD with 4-morpholinoaniline. Selected SipD peaks from A) 15N and B) ILV titrations of SipD with 4-morpholinoaniline. Plots of chemical shift deviation (CSD) of SipD with 4-morpholinoaniline based on C) 15N and D) ILV titrations (σ, average CSD).

Figure 9.

Figure 9

Surface of SipD affected by binding of 4-morpholinoaniline. Cα of SipD colored according to 15N and ILV chemical shift deviations as follows 1σ (yellow), 2σ (orange), 3σ (red); where σ is the standard deviation from average CSD in Figure 8.

SipB82–240 binds to 5-hydroxyindole and 3-indoleacetic acid

We also screened for small molecules that will bind to the major translocon protein SipB using the N-terminal soluble domain, SipB82–240. SPR identified the binding of 5-hydroxyindole (Figure 2C) and 3-indoleacetic acid (Figure 2D) to SipB82–240. NMR titrations of SipB82–240 with 5-hydroxyindole at protein to compound ratios of 1:0, 1:25 and 1:50 and monitored by 2D 1H-15N TROSY resulted in distinct chemical shift perturbations of specific SipB82–240 peaks in a concentration dependent manner (Figure S2A). Likewise, stepwise titration SipB82–240 with 3-indoleacetic acid at protein to compound ratios of 1:0, 1:4 and 1:8 resulted in distinct chemical shift perturbations of specific SipB82–240 peaks in a concentration dependent manner (Figure S2B). Likewise, the ILV methyl resonances of SipB82–240 were affected by titration with 5-hydroxyindole (Figure 10A) and 3-indoleacetic acid (Figure 10B). There are currently no NMR assignments available for SipB82–240, thus, it is not possible to use NMR chemical shift perturbation methods to identify which parts of SipB82–240 are involved in the interaction with 5-hydroxyindole or 3-indoleacetic acid. NMR assignments of SipB82–240 would have been challenging and not carried out because only ~50% of the expected amide resonances were observed (Figure S2)

Figure 10.

Figure 10

ILV titration of SipB82–240 with A) 5-hydroxyindole and B) 3-indoleacetic acid.

STD NMR confirmed the binding of 5-hydroxyindole and 3-indoleacetic to SipB82–240. Further, STD NMR identified how 5-hydroxyindole and 3-indoleacetic acid bound to SipB82–240. The off-resonance reference spectra show both compound and SipB82–240 signals present (Figure 11A, D). The resulting 1H STD NMR spectra show many of the signals corresponding to 3-indoleacetic acid (Figure 11B) and 5-hydroxyindole (Figure 11E) remained above noise level. This suggests that most of 5-hydroxyindole or 3-indoleacetic acid interacting with or in close proximity to SipB82–240. In contrast, irradiation of compounds using the same conditions in the absence of SipB82–240 resulted in no observable STD signals, indicating that SipB82–240 must be present to observe the STD signals of the compounds (Figure 11C, F).

Figure 11.

Figure 11

STD NMR of SipB with (A-C) 3-indoleacetic acid and (D-F) 5-hydroxyindole.

(A, D) Off-resonance and (B, E) on-resonance STD NMR spectra of SipB with the small molecules. (C, F) STD NMR of the small molecules in the absence of SipB82–240.

Discussion

There are currently only a few small molecules that are known to bind to the T3SS tip and translocon proteins. Bile salts, such as deoxycholate, are sterol-like compounds that bind to SipD and its Shigella homolog IpaD.[6a, 6b, 10, 13] Cholesterol and sphingolipids bind to the translocon protein SipB and its Shigella homolog IpaB.[11, 14] Finally, 2,2′-thiobis-(4-methylphenol) binds to the translocon protein YopD of Yersinia pestis.[15] Here, we identified new small molecule scaffolds (Figure 1) that bind to SipD (5-hydroxyindole and 4-morpholinoaniline) and SipB82–240 (5-hydroxyindole and 3-indoleacetic acid).

Comparison of the results of NMR titrations (Figure 3, Figure 5, Figure 8) suggests that 5-hydroxyindole (Figure 6) or 4-morpholinoaniline (Figure 9) perturbed similar surfaces on SipD. Both compounds affected SipD residues near the mixed α/β domain and the bottom region of the coiled-coil (Figure 6 and Figure 9). The bottom of the coiled-coil of SipD was previously identified as an important surface for the interaction with the needle protein PrgI.[16] Therefore, it may be possible to block the SipD:PrgI interaction by developing compounds that bind to SipD with higher affinity. Our efforts at co-crystallization of SipD or SipB82–240 with their interacting compounds has so far failed. Development of tighter binding compounds should allow co-crystallization to characterize binding by X-ray diffraction.

The observation that two surfaces on SipD were affected by the compounds could be because both compounds have weak affinity to SipD (~30 mM for 5-hydroxyindole) and are therefore not very selective for a specific binding surface. The perturbations of methyl ILV resonances of SipD with both 5-hydroxyindole (Figure 4) and 4-morpholinoaniline (Figure 8B, D) suggest that the protein-small molecule interaction included hydrophobic contacts. However, the small molecules also bound to SipD by polar interactions (perhaps by hydrogen bonding or ionic contacts) because many charged SipD residues were affected as well (Figure 2B and Figure 3B). This interaction with hydrophobic and hydrophilic surfaces is possible because the compounds contain hydrophobic rings as well as hydrophilic groups that are available for hydrogen bonding, such as OH and NH (Figure 1).

Indole-like chemical scaffolds have not been identified as inhibitors of T3SS.[3] In contrast, molecules that are somewhat chemically related to the aniline scaffold have been previously shown to inhibit type III secretion, such as salicylideneaniline and the 8-hydroxyquinoline derivative INP1750.[3] Salicylideneanilines (salicylidene + aniline like scaffold) have been suggested to function as a transcriptional inhibitor of the E. coli T3SS,[17] although the specific molecular target has not been identified, while the mechanism of INP1750 (quinoline + piperazine + aniline like scaffold) is currently unknown.[18] Because the tip and translocon proteins are conserved in many bacterial pathogens, it may be possible that more potent binding versions of indole and morpholinoaniline scaffolds might interact with homologs of SipD, such as IpaD from Shigella, BipD from Burkholderia, LcrV from Yersinia and PcrV from Pseudomonas. Indeed, some T3SS inhibitors, such as thiazolidinones[19] and salicylidene acylhydrazides,[20] have been shown to be active against a broad range of bacteria, suggesting their target is a conserved T3SS protein.[3] Efforts are currently underway to determine if 5-hydroxyindole, 3-indoleacetic acid or 4-morpholinoaniline interact with proteins from other bacterial T3SS systems.

To summarize, the significance of this work is that we have identified new small molecules based on the indole and aniline scaffolds that interact with the Salmonella translocon protein SipB and the tip protein SipD. These scaffolds could be used as potential starting structures in the rational design of inhibitors of type III secretion.

Experimental Section

Expression and Purification of SipD and SipB82–240

The expression and purification of SipD (residues 39–343 C244S) has been described previously.[6a] The construct SipB82–240 was designed based on the crystal structure of SipB82–226.[8] SipB82–240 was PCR amplified from Salmonella typhimurium LT2 strain and subcloned in the NdeI/XhoI sites of pET-22b. The SipD construct contained an N-terminal solubility tag of His6-GB1 domain and a tobacco etch virus (TEV) protease cleavage site whereas the SipB82–240 construct retained an 8-residue non-cleavable C-terminal his tag (LEH6). Plasmids for protein expression were transformed into E. coli DNAY BL21(DE3) and culture media contained kanamycin (30 µg/mL) and carbenicillin (100 µg/mL). Unlabeled proteins for SPR screening were obtained by cell growth in 1 liter of LB medium. Proteins for NMR were labeled simultaneously with 15N and ILV (where the methyl groups of isoleucine, leucine, and valine were 13C-labeled) by cell growth in M9 minimal medium supplemented with 1 g/L 15N-ammonium chloride (Sigma). Cells were grown at 37°C, when OD600 reached ~0.4, the growth medium was supplemented with 60 mg/L of 2-ketobutyric acid-4-13C sodium salt hydrate (#571342, Sigma) and 100 mg/L of 2-keto-3-(methyl-13C)-butyric-4-13C acid sodium salt (#571334, Sigma). When OD600 reached ~0.8, cells were induced with 1 mM isopropyl-β-D-thiogalactopyrandoside (IPTG) and cell growth was continued overnight at 15°C to a final OD600 of ~2.6 (for LB) and ~2.1 (for M9).

Cells were harvested by centrifugation (4000 rpm, 10 min), resuspended in buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0, 1 mM phenylmethanesulfonyl fluoride) and sonicated. Cell lysate was centrifuged (13,000 rpm, 10 min), and 700 µL of 5% polyethyleneimine was added to the supernatant to precipitate the nucleic acid, followed by centrifugation (13,000 rpm, 10 min). The supernatant was loaded on a 5 mL Ni2+-affinity resin (Gold Biotechnology) and washed with 150 mL of binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0). SipD or SipB82–240 was eluted from the Ni2+ column with 40 mL of elution buffer (500 mM NaCl, 20 mM Tris-HCl, 250 mM imidazole, pH 8.0). To remove the His6-GB1 tag in the SipD construct, fractions were pooled and incubated overnight with 250 µL of 0.04 mM recombinant TEV protease[21] in buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 1 mM DTT, 20 mM NaCl) at room temperature and the digest was passed through a 5 mL Ni2+-affinity column, which retained the His6-GB1 tag. Proteins were dialyzed into either 1.05× phosphate-buffered saline (PBS, pH 7.4) or NMR buffer (20 mM NaCl, 10 mM sodium phosphate, pH 7.4) and concentrated using Amicon Ultra 3K (Millipore) filtration columns. Protein concentrations were determined by absorbance at A280.

SPR Screening

Surface Plasmon Resonance (SPR) was used for screening using a Biacore 3000 instrument (GE Healthcare). The amine coupling kit (#BR-1106-33) and CM5 sensor chip (#BR100399) were purchased from GE Healthcare. The target proteins SipD and SipB82–240 were covalently immobilized to the sensor chip surface by standard amine coupling chemistry with 1.05× PBS buffer as the running buffer. There were four flow cells available for immobilization of target protein per CM5 chip. Flow cell 1 was kept as reference flow cell without immobilized protein. The remaining 3 flow cells were loaded with target proteins. All four flow cells were activated for 7 minutes with a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) at 1:1 ratio and at a flow rate of 15 µL/min at 25°C. Proteins at a concentration of 50 µg/mL in 10 mM sodium acetate (pH 4.3) were injected for 7 minutes resulting in 2,727 response units (RU) for SipB82–240 and 10,110 RU for SipD. All four flow cell surfaces were treated with a 7 minute injection of 1M ethanolamine (pH 8.0) to eliminate all the unbound proteins and unreacted esters of NHS/EDC from the flow cells.

A library of 288 compounds (Fragment Library 2, Zenobia, San Diego) was obtained in three 96-well microplates, with each compound at a concentration of 100 mM stock in 100% DMSO. Compounds were diluted to final concentration of 1 mM in 5% DMSO and 1.05× PBS. Biacore 3000 allowed the automated injection of compounds from 96-well plates. The compounds were injected over the chip surface for 60 sec at a flow rate of 60 µL/min and the dissociation was monitored for 60 sec. Running buffer (1.05× PBS) was used as negative control. The surface was not regenerated between sample injections. The flow system, except sensor surface, was washed with 1:1 mixture of DMSO and water to remove any unbound compound from the flow system. Running buffer was injected between each compound run to monitor carryover effects. Eight DMSO calibration solutions with varying concentrations (4–6%) were injected sequentially at the beginning and end of the experiments, using the same flow rate as for the compounds.

NMR Spectroscopy

NMR data were acquired using a Bruker Avance 800 MHz spectrometer equipped with a cryogenic triple resonance probe and were processed using NMRPipe[22] and analyzed using NMRView.[23] Saturation transfer difference (STD) NMR data were acquired using a Bruker Avance 600 MHz spectrometer equipped with a TXI-RT probe and processed using Topspin. Two-dimensional 1H-15N TROSY and 1H-13C HSQC spectra were acquired at 30°C using 0.3 mM of 15N/ILV SipD or 0.5 mM of 15N/ILV SipB82–240 in buffer (10 mM sodium phosphate pH 7.4, 20 mM NaCl, and 10% D2O). For NMR titrations, the compounds were dissolved in d6-DMSO (Cambridge Isotope Laboratories, Inc., Andover, MA). All titration samples for NMR contained 1.5% (v/v) d6-DMSO for SipD or 2.5% (v/v) d6-DMSO for SipB82–240. Typical 2D 1H-15N TROSY acquisition parameters were 16 scans at 30 ppm 15N sweep width centered at 118 ppm, whereas typical 2D 1H-13C HSQC acquisition parameters for ILV-labeled samples were 8 scans, 18 ppm 13C sweep width centered at 18 ppm and 10 ppm 1H sweep width centered at 4.69 ppm. Chemical shift deviation (Δδ) was calculated using ΔδHN = [½ (ΔδH2 + ΔδN2/25)]1/2 [24] for backbone amides and ΔδILV = [½ (ΔδH2 + ΔδC2/4)]1/2 for ILV labels. Dissociation constants were estimated from plots of chemical shift deviation vs. compound concentration for multiple residues and curve fitting using GraphPad Prism Version 5 (GraphPad Software, Inc., USA). The R2 values for the fits were ≥ 0.99.

One-dimensional 1H Saturation Transfer Difference (STD) NMR[25] data were acquired at 30°C on samples containing protein plus compound at a 1:100 molar ratio (40 µM protein, 4000 µM compound, 10% D2O, 0.4% d6-DMSO) or compound only (4000 µM compound in 100% d6-DMSO). The protein saturation pulse (Gaussian) was 50 ms over a period of 2 sec with the center of the on-resonance pulse varied from −0.2 to 0.1 ppm to give an optimal STD signal, while the off-resonance center was kept at 40 ppm. Typical acquisition parameters were 128 scans, 16 ppm 1H sweep width centered at 4.701 ppm, and 2 sec recycle delay.

Supplementary Material

Supporting Information

Acknowledgments

We are grateful to Srirupa Chatterjee for the SipB82–240 plasmid and to Supratim Dey and Kawaljit Kaur for helpful discussions. This work was supported by National Institutes of Heath grants AI074856 (R.N.G.), T32-GM008359 (A.C.M. and S.P.) and P30-GM110761 (University of Kansas Biomolecular NMR Core Facility); and the University of Kansas Strategic Initiative Grant #INS72410 (R.N.D.).

Abbreviations

NMR

nuclear magnetic resonance

CSD

chemical shift deviation

SPR

surface plasmon resonance

STD

saturation transfer difference

T3SS

type III secretion system

References

  • 1.Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM. S. International Collaboration on Enteric Disease 'Burden of Illness. Clin. Infect. Dis. 2010;50:882–889. doi: 10.1086/650733. [DOI] [PubMed] [Google Scholar]
  • 2.Galan JE, Lara-Tejero M, Marlovits TC, Wagner S. Annu. Rev. Microbiol. 2014;68:415–438. doi: 10.1146/annurev-micro-092412-155725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.McShan AC, De Guzman RN. Chem. Biol. Drug. Des. 2015;85:30–42. doi: 10.1111/cbdd.12422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.a) Chatterjee S, Chaudhury S, McShan AC, Kaur K, De Guzman RN. Biochemistry. 2013;52:2508–2517. doi: 10.1021/bi400160a. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Mueller CA, Broz P, Cornelis GR. Mol. Microbiol. 2008;68:1085–1095. doi: 10.1111/j.1365-2958.2008.06237.x. [DOI] [PubMed] [Google Scholar]
  • 5.Lara-Tejero M, Galan JE. Infect. Immun. 2009;77:2635–2642. doi: 10.1128/IAI.00077-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.a) Chatterjee S, Zhong D, Nordhues BA, Battaile KP, Lovell SW, De Guzman RN. Protein Sci. 2011;20:75–86. doi: 10.1002/pro.537. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Lunelli M, Hurwitz R, Lambers J, Kolbe M. PLoS Pathog. 2011;7:e1002163. doi: 10.1371/journal.ppat.1002163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.a) Chaudhury S, Battaile KP, Lovell S, Plano GV, De Guzman RN. Acta Crystallogr. Sect. F. 2013;69:477–481. doi: 10.1107/S1744309113008579. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Johnson S, Roversi P, Espina M, Olive A, Deane JE, Birket S, Field T, Picking WD, Blocker AJ, Galyov EE, Picking WL, Lea SM. J. Biol. Chem. 2007;282:4035–4044. doi: 10.1074/jbc.M607945200. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Derewenda U, Mateja A, Devedjiev Y, Routzahn KM, Evdokimov AG, Derewenda ZS, Waugh DS. Structure. 2004;12:301–306. doi: 10.1016/j.str.2004.01.010. [DOI] [PubMed] [Google Scholar]
  • 8.Barta ML, Dickenson NE, Patil M, Keightley A, Wyckoff GJ, Picking WD, Picking WL, Geisbrecht BV. J. Mol. Biol. 2012;417:395–405. doi: 10.1016/j.jmb.2012.01.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dickenson NE, Arizmendi O, Patil MK, Toth RTt, Middaugh CR, Picking WD, Picking WL. Biochemistry. 2013;52:8790–8799. doi: 10.1021/bi400755f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wang Y, Nordhues BA, Zhong D, De Guzman RN. Biochemistry. 2010;49:4220–4226. doi: 10.1021/bi100335u. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hayward RD, Cain RJ, McGhie EJ, Phillips N, Garner MJ, Koronakis V. Mol. Microbiol. 2005;56:590–603. doi: 10.1111/j.1365-2958.2005.04568.x. [DOI] [PubMed] [Google Scholar]
  • 12.Arkin MR, Wells JA. Nat. Rev. Drug Discov. 2004;3:301–317. doi: 10.1038/nrd1343. [DOI] [PubMed] [Google Scholar]
  • 13.a) Barta ML, Guragain M, Adam P, Dickenson NE, Patil M, Geisbrecht BV, Picking WL, Picking WD. Proteins. 2012;80:935–945. doi: 10.1002/prot.23251. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Dickenson NE, Zhang L, Epler CR, Adam PR, Picking WL, Picking WD. Biochemistry. 2011;50:172–180. doi: 10.1021/bi101365f. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Stensrud KF, Adam PR, La Mar CD, Olive AJ, Lushington GH, Sudharsan R, Shelton NL, Givens RS, Picking WL, Picking WD. J. Biol. Chem. 2008;283:18646–18654. doi: 10.1074/jbc.M802799200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lafont F, Tran Van Nhieu G, Hanada K, Sansonetti P, van der Goot FG. EMBO J. 2002;21:4449–4457. doi: 10.1093/emboj/cdf457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jessen DL, Bradley DS, Nilles ML. Antimicrob. Agents Chemother. 2014;58:839–850. doi: 10.1128/AAC.01170-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.a) Rathinavelan T, Lara-Tejero M, Lefebre M, Chatterjee S, McShan AC, Guo DC, Tang C, Galan JE, De Guzman RN. J. Mol. Biol. 2014;426:2958–2969. doi: 10.1016/j.jmb.2014.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Rathinavelan T, Tang C, De Guzman RN. J. Biol. Chem. 2011;286:4922–4930. doi: 10.1074/jbc.M110.159434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL, Finlay BB. Antimicrob. Agents Chemother. 2005;49:4101–4109. doi: 10.1128/AAC.49.10.4101-4109.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Enquist PA, Gylfe A, Hagglund U, Lindstom P, Norberg-Scherman H, Sundin C, Elofsson M. Bioorg. Med. Chem. Lett. 2012;22:3550–3553. doi: 10.1016/j.bmcl.2012.03.096. [DOI] [PubMed] [Google Scholar]
  • 19.a) Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, Blanc MP, Bronstein PA, Kline T, Miller SI. Cell Host Microbe. 2008;4:325–336. doi: 10.1016/j.chom.2008.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Kline T, Barry KC, Jackson SR, Felise HB, Nguyen HV, Miller SI. Bioorg. Med. Chem. Lett. 2009;19:1340–1343. doi: 10.1016/j.bmcl.2009.01.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wang D, Zetterstrom CE, Gabrielsen M, Beckham KS, Tree JJ, Macdonald SE, Byron O, Mitchell TJ, Gally DL, Herzyk P, Mahajan A, Uvell H, Burchmore R, Smith BO, Elofsson M, Roe AJ. J. Biol. Chem. 2011;286:29922–29931. doi: 10.1074/jbc.M111.233858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Geisbrecht BV, Bouyain S, Pop M. Protein Expr. Purif. 2006;46:23–32. doi: 10.1016/j.pep.2005.09.003. [DOI] [PubMed] [Google Scholar]
  • 22.Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. J. Biomol. NMR. 1995;6:277–293. doi: 10.1007/BF00197809. [DOI] [PubMed] [Google Scholar]
  • 23.Johnson BA. Methods Mol. Biol. 2004;278:313–352. doi: 10.1385/1-59259-809-9:313. [DOI] [PubMed] [Google Scholar]
  • 24.Grzesiek S, Stahl SJ, Wingfield PT, Bax A. Biochemistry. 1996;35:10256–10261. doi: 10.1021/bi9611164. [DOI] [PubMed] [Google Scholar]
  • 25.Mayer M, Meyer B. Angew. Chem. Int. Ed. 1999;38:1784–1788. doi: 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES